RecruitingPhase 4NCT07391579

Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients

Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients: A Multicenter Randomized, Double-Blind, Placebo-Controlled Trial


Sponsor

Mansoura University

Enrollment

500 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to evaluate whether daily dosing with tadalafil 5 mg combined with on-demand sildenafil 100 mg can improve erectile function in men with erectile dysfunction (ED) who do not respond to PDE5 inhibitor alone. The main questions it aims to answer are: * Does the combination of daily tadalafil and on-demand sildenafil lead to a greater improvement in erectile function (measured by the IIEF-EF domain) compared with on-demand sildenafil alone? * Is the combination therapy safe and well tolerated in this patient population? Researchers will compare: * Group A: Daily tadalafil 5 mg plus on-demand sildenafil 100 mg * Group B: Daily placebo plus on-demand sildenafil 100 mg to determine whether the combination regimen provides superior improvement in erectile function and patient satisfaction. Participants will: * Undergo baseline assessment including medical history, physical examination, and laboratory tests. * Be randomly assigned to one of the two treatment groups. * Take the assigned medications for 12 weeks. * Complete follow-up evaluations at 4, 8, and 12 weeks, including: International Index of Erectile Function (IIEF-15) questionnaire Erection Hardness Score (EHS) assessment Reporting of any adverse effects


Eligibility

Sex: MALEMin Age: 21 Years

Inclusion Criteria5

  • Sexually active male.
  • History of ED for ≥6 months.
  • Erectile function domain of IIEF-15 score <17.
  • Documented failure to respond to PDE-5I \[definition of non-responder patients are patients with ED who don't respond to maximum dose of PDE-5I on ≥4 occasions in spite of accurate timing and good sexual stimulation\].
  • Stable sexual relationship ≥ 6 months.

Exclusion Criteria6

  • Penile anatomical deformities or Peyronie's disease.
  • Pelvic surgery or radiation.
  • Active malignancy or severe systemic illness.
  • Previous penile surgery of any kind, such as penile prosthesis, penile lengthening, penile cancer surgery, penile plication or grafting.
  • Contraindication to PDE5i (High risk cardiac patients, patients on nitrates, hypotension).
  • Using other treatments for ED e.g., Intra-cavernoasl prostaglandin injection therapy.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTadalafil 5 mg & Sildenafil 100mg

daily dosing of Tadalafil 5 mg combined with on demand Sildenafil 100mg

DRUGSildenafil 100mg & placebo

Daily Placebo combined with on demand Sildenafil 100mg


Locations(11)

Urology and Nephrology Center, Mansoura University

Al Mansurah, Dakahlia Governorate, Egypt

Faculty of medicine, Alexandria University

Alexandria, Egypt

Faculty of medicine, Aswan university

Aswān, Egypt

Faculty of Medicine - Assiut University

Asyut, Egypt

Cairo University, faculty of medicine

Cairo, Egypt

Faculty of medicine, Ain Shams University

Cairo, Egypt

Faculty of medicine, Azhar University

Cairo, Egypt

Faculty of medicine, october 6 Univeristy

Cairo, Egypt

Faculty of medicine, Luxor university

Luxor, Egypt

faculty of medicine, Minya University

Minya, Egypt

Faculty of medicine, Tanta University

Tanta, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07391579


Related Trials